fluoxetine has been researched along with perphenazine in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (23.81) | 18.2507 |
| 2000's | 7 (33.33) | 29.6817 |
| 2010's | 9 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Ang, KK; Arkin, MR; Chen, S; Doyle, PS; Engel, JC; McKerrow, JH | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Glickman, L; Lampke, R; Viswanathan, R | 1 |
| Rothschild, AJ | 1 |
| Bessette, MP; Carter-Campbell, JT; Rothschild, AJ; Samson, JA | 1 |
| Benjamin, S; Connor, DF; Ozbayrak, KR | 1 |
| De Meester, I; Desnyder, R; Maes, M; Meltzer, HY; Ranjan, R; Scharpe, S | 1 |
| Diaz, A; Fouilloux, C; Ortiz, S | 1 |
| Duval, SE; Rothschild, AJ | 1 |
| Ahmadi, A; Khazaie, H; Moradi, M; Tahmasian, M | 1 |
| D'Ambrosio, JC; Raguveer, V; Varshney, A | 1 |
1 review(s) available for fluoxetine and perphenazine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 trial(s) available for fluoxetine and perphenazine
| Article | Year |
|---|---|
Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression.
Topics: Adult; Amoxapine; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Drug Therapy, Combination; Electroconvulsive Therapy; Female; Fluoxetine; Humans; Male; Middle Aged; Perphenazine; Psychiatric Status Rating Scales | 1993 |
Open trial study of a combined antidepressant (amitryptiline, perphenazine, diazepam) versus fluoxetine or imipramine in ambulatory depressed patients.
Topics: Adolescent; Adult; Amitriptyline; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Depressive Disorder; Diazepam; Drug Combinations; Female; Fluoxetine; Humans; Imipramine; Male; Middle Aged; Perphenazine; Prospective Studies; Psychiatric Status Rating Scales | 2002 |
How long should patients with psychotic depression stay on the antipsychotic medication?
Topics: Acute Disease; Adult; Affective Disorders, Psychotic; Antipsychotic Agents; Clinical Protocols; Depressive Disorder; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Middle Aged; Perphenazine; Prospective Studies; Psychiatric Status Rating Scales; Secondary Prevention; Time Factors | 2003 |
17 other study(ies) available for fluoxetine and perphenazine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
Topics: Animals; Cattle; Cell Line; Cell Line, Tumor; Chagas Disease; Drug Evaluation, Preclinical; Hepatocytes; High-Throughput Screening Assays; Humans; Image Processing, Computer-Assisted; Muscle, Skeletal; Parasitic Sensitivity Tests; Trypanocidal Agents; Trypanosoma cruzi | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Cessation of menses due to perphenazine rather than fluoxetine?
Topics: Amenorrhea; Female; Fluoxetine; Humans; Menstruation; Perphenazine | 1990 |
Delirium: an SSRI-benztropine adverse effect?
Topics: Adult; Age Factors; Aged; Benztropine; Delirium; Drug Interactions; Fluoxetine; Humans; Middle Aged; Perphenazine; Schizophrenia; Selective Serotonin Reuptake Inhibitors | 1995 |
Case study: neuroleptic withdrawal dyskinesia exacerbated by ongoing stimulant treatment.
Topics: Antipsychotic Agents; Dextroamphetamine; Diphenhydramine; Fluoxetine; Humans; Male; Mental Disorders; Movement Disorders; Perphenazine; Psychiatric Status Rating Scales; Substance Withdrawal Syndrome; Videotape Recording | 1995 |
Alterations in plasma dipeptidyl peptidase IV enzyme activity in depression and schizophrenia: effects of antidepressants and antipsychotic drugs.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Female; Fluoxetine; Haloperidol; Humans; Hydrocortisone; Imipramine; Male; Middle Aged; Nortriptyline; Perphenazine; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology | 1996 |
Treatment of idiopathic recurrent priapism with fluoxetine and low dose Perphenazine.
Topics: Adult; Antipsychotic Agents; Anxiety; Depression; Fluoxetine; Humans; Male; Perphenazine; Priapism; Secondary Prevention; Selective Serotonin Reuptake Inhibitors | 2008 |
Serotonin Syndrome: Difficult to Diagnose but Critical to Treat.
Topics: Adult; Antipsychotic Agents; Cyproheptadine; Diagnosis, Differential; Female; Fluoxetine; Humans; Perphenazine; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Serotonin Syndrome | 2015 |